Enovis Corporation $ENOV Stock Position Increased by First National Advisers LLC

First National Advisers LLC raised its position in shares of Enovis Corporation (NYSE:ENOV) by 17.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,003 shares of the company’s stock after purchasing an additional 2,114 shares during the period. First National Advisers LLC’s holdings in Enovis were worth $439,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Elevation Point Wealth Partners LLC acquired a new position in shares of Enovis during the second quarter worth approximately $46,000. CWM LLC raised its stake in Enovis by 564.9% during the 2nd quarter. CWM LLC now owns 3,790 shares of the company’s stock valued at $119,000 after acquiring an additional 3,220 shares in the last quarter. McIlrath & Eck LLC raised its stake in Enovis by 52.2% during the 1st quarter. McIlrath & Eck LLC now owns 5,274 shares of the company’s stock valued at $202,000 after acquiring an additional 1,808 shares in the last quarter. Humankind Investments LLC boosted its position in Enovis by 8.6% during the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company’s stock worth $217,000 after acquiring an additional 452 shares during the period. Finally, Ameritas Investment Partners Inc. bought a new position in shares of Enovis in the second quarter worth $183,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on ENOV. UBS Group cut their price objective on shares of Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Needham & Company LLC dropped their price target on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Canaccord Genuity Group reduced their price target on shares of Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company boosted their target price on Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $51.17.

Enovis Stock Performance

Shares of ENOV opened at $30.27 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The firm’s 50 day moving average is $30.70 and its 200-day moving average is $30.93. Enovis Corporation has a 12-month low of $25.47 and a 12-month high of $49.75. The stock has a market capitalization of $1.73 billion, a P/E ratio of -2.12 and a beta of 1.67.

Enovis (NYSE:ENOV) last issued its earnings results on Monday, January 8th. The company reported $0.59 earnings per share for the quarter. The firm had revenue of $383.81 million during the quarter. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. Equities research analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Insider Buying and Selling at Enovis

In related news, insider John Kleckner purchased 2,468 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was acquired at an average price of $30.32 per share, for a total transaction of $74,829.76. Following the transaction, the insider directly owned 12,302 shares of the company’s stock, valued at $372,996.64. This trade represents a 25.10% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Damien Mcdonald purchased 6,457 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The stock was bought at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the purchase, the chief executive officer directly owned 102,753 shares in the company, valued at $3,182,260.41. This represents a 6.71% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 2.70% of the company’s stock.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.